Italfarmaco is a pharmaceutical company dedicated to research and developing treatments for various medical conditions. One area of focus for Italfarmaco is muscular dystrophies, a group of genetic diseases characterized by progressive muscle weakness and loss of mobility. Duchenne Muscular Dystrophy (DMD), the most common form of muscular dystrophy, primarily affects boys and is caused by the absence of the dystrophin protein.

Italfarmaco is actively involved in clinical trials for Givinostat, a potential treatment for DMD. In addition to muscular dystrophies, Italfarmaco also specializes in therapeutic areas such as thrombosis and critical ischemia, cardiovascular and inflammatory diseases, immuno-oncology, gynecology, neurology, and psychiatry. With a strong commitment to patient safety and transparency, Italfarmaco strives to improve the quality of life for patients worldwide